$62.03
+0.064%GE HealthCare Technologies Inc. engages in the development, manufacture, and marketing of products, services, and complementary digital solutions used in the diagnosis, treatment, and monitoring of patients in the United States, Canada, Europe, the Middle East, Africa, China, Taiwan, Mongolia, Hong Kong, and internationally. The company operates through four segments: Imaging, Ultrasound, Patient Care Solutions, and Pharmaceutical Diagnostics. The Imaging segment offers molecular imaging, computed tomography (CT) scanning, magnetic resonance (MR) imaging, image-guided therapy, and X-ray systems, as well as women's health products. The Ultrasound segment provides screening, diagnosis, treatment, and monitoring of certain diseases through radiology and primary care, women's health, cardiovascular, and point of care and handheld ultrasound solutions, as well as surgical visualization and guidance products. The Patient Care Solutions segment involved in the provision of medical devices, consumable products, services, and digital solutions through patient monitoring, anesthesia delivery and respiratory care, diagnostic cardiology, and maternal infant care products. The Pharmaceutical Diagnostics supplies diagnostic agents, including CT, angiography and X-ray, MR, single-photon emission computed tomography, positron emission tomography, and ultrasound to the radiology and nuclear medicine industry. The segment also provides contrast media pharmaceuticals, administered to a patient prior to certain diagnostic scans to increase the visibility of tissues or structures during imaging exams; and molecular imaging agents, or radiopharmaceuticals, which are molecular tracers labeled with radioisotopes that are injected into a patient prior to a diagnostic imaging scan. The company was incorporated in 2022 and is headquartered in Chicago, Illinois.
Wall Street analysts project that GEHC stock may rise significantly over the coming 12 months. The consensus 1-year price target stands at 83.27, with estimates ranging from a low of 65.00 to a high of 105.00.
The consensus 1-year price target stands at 83.27, with estimates ranging from a low of 65.00 to a high of 105.00.
Substantial upside potential. Analysts see significant value gap, suggesting the stock may be materially undervalued at current levels.
Mixed analyst views. Wide target range suggests differing opinions on key value drivers, growth prospects, or risk factors.
Neutral sentiment. Fair value pricing with moderate agreement suggests wait-and-see approach or catalyst-driven opportunity.
Monitor and evaluate: Current analyst consensus suggests limited conviction or near-term catalysts. Stay informed on company developments and reassess positioning as new information emerges.
Flat growth suggests market maturity or near-term challenges offsetting expansion efforts.
Good analyst coverage ensures reliable estimates with diverse professional perspectives.
Narrow estimate range signals strong analyst consensus and predictable business outlook.
Generally favorable outlook with reasonable growth prospects and analyst support.
Moderate growth expected, typical for mature businesses with stable market positions.
Good analyst coverage ensures reliable estimates with diverse professional perspectives.
Narrow estimate range signals strong analyst consensus and predictable business outlook.
Positive analyst consensus with strong growth expectations and forecast confidence.
Moderate growth expected, typical for mature businesses with stable market positions.
Good analyst coverage ensures reliable estimates with diverse professional perspectives.
Narrow estimate range signals strong analyst consensus and predictable business outlook.
Positive analyst consensus with strong growth expectations and forecast confidence.
Flat growth suggests market maturity or near-term challenges offsetting expansion efforts.
Good analyst coverage ensures reliable estimates with diverse professional perspectives.
Narrow estimate range signals strong analyst consensus and predictable business outlook.
Generally favorable outlook with reasonable growth prospects and analyst support.
Moderate growth expected, typical for mature businesses with stable market positions.
Good analyst coverage ensures reliable estimates with diverse professional perspectives.
Narrow estimate range signals strong analyst consensus and predictable business outlook.
Positive analyst consensus with strong growth expectations and forecast confidence.
Flat growth suggests market maturity or near-term challenges offsetting expansion efforts.
Good analyst coverage ensures reliable estimates with diverse professional perspectives.
Narrow estimate range signals strong analyst consensus and predictable business outlook.
Generally favorable outlook with reasonable growth prospects and analyst support.
During the last 12 months, insiders have purchased $6.42M worth of GEHC shares, with no selling activity reported.
103.7K
6.42M
0
0.00
+6.4M
+$6.42M
0
0.00
0
0.00
+0
+$0
0
0.00
0
0.00
+0
+$0
0
0.00
0
0.00
+0
+$0
Culp H Lawrence Jr
Director
$5.00M
Lobo Kevin
Director
$642K
Arduini Peter J
Director, Officer: President And Ceo
$250K
Saccaro James
Officer: Chief Financial Officer
$201K
Jimenez Frank R
Officer: Gc & Corporate Secretary
$106K
No selling activity
Strong bullish signal with $6.42M net buying. Insiders are aggressively accumulating shares, suggesting significant confidence in future prospects.
Perfect buy/sell ratio. Only buying activity with zero sellingโthe most bullish possible insider signal.
Very strong recent buying momentum. Recent insider purchases significantly outpace sales, suggesting near-term optimism.
5 insider buyers vs. 0 sellers. Broad-based buying across management team suggests widespread confidence.
Strong confluence of bullish signals: High buy/sell ratio, multiple insiders participating, and recent buying momentum all point to significant insider confidence. This level of coordinated buying often precedes positive developments.
Continue your GEHC research with focused valuation guides.
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.